Cisplatin nephrotoxicity in a patient with a single kidney

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 782-786

  Udeani, George O ^a   Singh, Karanjit ^b   Mullane, Michael R ^a   Lad, Thomas E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

AGED; AGING; ARTICLE; CASE REPORT; CIRCADIAN RHYTHM; CREATININE BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; SOLITARY KIDNEY; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; UREA NITROGEN BLOOD LEVEL;

EID: 0030035092     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000715     Document Type: Article

References (24)

1. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979;63:1527-31.
2. Madias NE, Harrington ST. Platinum nephrotoxicity. Am J Med 1978; 65:307-14.
3. Lippman AJ, Helson C, Helson L, Krakoff IH. Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 1973; 57:191-200.
4. Stewart DJ, Mlkhael NZ, Nanji AA, Nair RC, Kacew S, Howard K, et al. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 1985;3:1251-6.
5. Nanji AA, Stewart DJ, Mikhael NZ. Cisplatin nephrotoxicity: relationship to pretreatment levels of uric acid and albumin (abstract). Clin Pharmacol Ther 1985;37:216.
6. Offerman JJG, Meijer S, Sleijfer DTH, Mulder NH, Donker AJM, Koops HS, et al. Acute effects of cis-diammine dichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 1984;12:36-8.
7. Offerman JJG, Sleijfer DTH, Mulder NH, Meijer S, Koops HS, Donker AJM, et al. The effect of captopril on renal function in patients during the first cis-diamminedichloroplatinum II infusion. Cancer Chemother Pharmacol 1985;14:262-4.
8. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986;5:356-67.
9. Sleijfer DTH, Offerman JJG, Mulder NH, Verweij M, Van Der Hem GK, Koops HS, et al. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 1987;60:2823-8.
10. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 1991;67:1518-24.
11. Qazi R, Chang AYC, Borch Rf, Montine T, Dedon P, Loughner J, et al. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst 1988;80:1486-8.
12. Ozols RF, Young RC. High-dose cisplatin therapy in ovarian cancer. Semin Oncol 1985;12:21-30.
13. Howell SB, Pfeifle CL, Wang WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51.
14. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984;100:19-24.
15. Hrushesky WJM, Borch R, Levi F. Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Thera 1982;32:330-9.
16. Hrushesky WJM, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984;76:579-84.
17. Sothern RB, Halberg F, Hrushesky W. Circadian optimization of cis-diamminedichloroplatinum (Pl) and adriamycin (Ad) combination (PlAd) therapy of an immunocytoma gauged by complete remission or cure (abstract). Clin Res 1978;26:712A.
18. Lichtman SM, Buchholtz M, Marino J, Schulman P, Allen SL, Weiselberg L, et al. Use of cisplatin for elderly patients. Age Ageing 1992;21 : 202-4.
19. Anderson S, Brenner BM. The aging kidney: structure, function, mechanisms, and therapeutic implications. J Am Geriatr Soc 1987;35:590-3.
20. De Gislain C, Dumas M, Dathis P, Chapuis T, Mayer F, Fargeot P, et al. Plasma creatinine evolution in long term cisplatin therapy - influence of drug associations. Therapie 1990;45:423-7.
21. Furuta N, Machida T, Masuda F, Nakada J, Onishi T, Kondo I, et al. A clinical report of nephrotoxicity due to cisplatin. Jpn J Clin Urol 1989; 43:253-7.
22. Reed E, Jacob J, Brawley O. Measures of renal function in patients with cisplatin-related chronic renal disease. J Natl Med Assoc 1991;83:522-6.
23. Tsujimura A, Takayama H, Tsukikawa M, Imazu T, Sugao H, Takaha M. Clinical studies of chemotherapy for patients with solitary kidney after nephrouretectomy for advanced upper urothelial transitional cell carcinoma. Hinyokika Kiyo 1995;41:183-9.
24. Levi F, Hrushesky WJ, Borch RF. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. Cancer Treat Rep 1982;66:1933-8.